Nabriva Therapeutics AG   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Vienna Austria (2001)

Organization Overview

First Clinical Trial
2010
NCT01119105
First Marketed Drug
2019
lefamulin (Xenleta)
First NDA Approval
2019
lefamulin (Xenleta)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NABRIVA | Nabriva Therapeutics | Nabriva Therapeutics AG

Active Ingredients

Marketed Drugs (1)

lefamulin (Xenleta) (2019 NDA)

Drugs in Phase 3 Trials (6)

Key: Nabriva Therapeutics AG (3) Acquired (3)

fosfomycin (monurol) (3 trials)

lefamulin (Xenleta) (7 trials)

linezolid (zyvox) (1 trial)

moxifloxacin (avelox) (3 trials)

piperacillin (pipracil) (1 trial)

tazobactam (Zosyn) (1 trial)

Drugs in Phase 2 Trials (2)

doxycycline (vibramycin) (1 trial)

vancomycin (Vancocin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 2)

Communicable Diseases (Phase 2)

Infections (Phase 2)

Pneumonia (Phase 3)

Skin Diseases, Bacterial (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 8